Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT06340243 Not yet recruiting - Clinical trials for Pediatric Hodgkin Lymphoma

Risk Adapted Therapy of Hodgkin Lymphoma in Upper Egypt

Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

determine if radiotherapy could be safely omitted for early hodgkin lymphoma responder patients without compromising outcome

NCT ID: NCT06337318 Not yet recruiting - Clinical trials for Classic Follicular Lymphoma

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Start date: August 31, 2024
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.

NCT ID: NCT06334991 Not yet recruiting - Clinical trials for Non-Hodgkin Lymphoma Refractory/ Relapsed

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Start date: July 1, 2024
Phase: Phase 1
Study type: Interventional

Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).

NCT ID: NCT06332430 Not yet recruiting - Lymphoma Clinical Trials

Intratumoral CAN2109 in Subjects With Solid Tumors or Lymphomas

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

A phase 1, dose escalation, open-label study of intratumoral CAN2109 in subjects with unstable or metastatic advanced solid tumors or lymphomas.

NCT ID: NCT06326463 Not yet recruiting - Lymphoma Clinical Trials

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Start date: May 2024
Phase: Phase 1
Study type: Interventional

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma. Your cancer has been difficult to treat (refractory) or has come back after treatment (relapse). Primary Objective To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD70-CAR T cells in patients (≤21 years) with recurrent/refractory CD70+ hematological malignancies after lymphodepleting chemotherapy. Secondary Objectives To evaluate the antileukemic activity of CD70-CAR T cells. We will determine the anti- leukemic activity of the CD70-CAR T cells in the bone marrow and in the treatment of extramedullary disease.

NCT ID: NCT06324994 Not yet recruiting - Clinical trials for Mantle Cell Lymphoma

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Start date: May 1, 2024
Phase: Phase 2
Study type: Interventional

This is a single arm, open label, national multicenter clinical study included patients with relapsed and refractory blastoid variant of mantle cell lymphoma (R/R BV-MCL), aiming to evaluate the efficacy of a chemotherapy free triple therapy of PI3K inhibitor (Linperlisib) combined with anti-CD20 monoclonal antibody (Obinutuzumab) and BCL-2 inhibitor (Venetoclax) in R/R BV-MCL patients.

NCT ID: NCT06318884 Not yet recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Start date: April 2024
Phase: Phase 1
Study type: Interventional

This is a Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics, and preliminary efficacy of SCTB35 monotherapy, an bispecific antibody, in patients with relapsed and/or refractory B-cell non-Hodgkin lymphoma.

NCT ID: NCT06314828 Not yet recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Start date: May 20, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.

NCT ID: NCT06313996 Not yet recruiting - Clinical trials for Relapsed or Refractory Follicular Lymphoma

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Start date: March 29, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Liso-cel compared to standard of care in adults with Relapsed or Refractory Follicular Lymphoma.

NCT ID: NCT06300528 Not yet recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well pemigatinib works in treating patients with mantle cell lymphoma (MCL) or marginal zone lymphoma (MZL) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Pemigatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.